



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification : A61K 39/12		A2	(11) International Publication Number: WO 00/06196
			(43) International Publication Date: 10 February 2000 (10.02.00)
(21) International Application Number: PCT US99/17036		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 27 July 1999 (27.07.99)			
(30) Priority Data: 60/094,425 28 July 1998 (28.07.98) US			
(71) Applicant (for all designated States except US): THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; National Institutes of Health Office of Technology Transfer, Box OTT, Bethesda, MA 20892-9902 (US).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): KAPIKIAN, Albert, H. [US/US]; 11201 Marcliff Road, Rockville, MD 20892 (US). CHANOCK, Robert, M. [US/US]; 7001 Longwood Drive, Bethesda, MD 20817 (US). HOSHINO, Yasutaka [JP/US]; 2111 Cambridge Part Court, Wheaton, MD 20902 (US).			
(74) Agents: POOR, Brian, W. et al.; Townsend and Townsend and Crew LLP, Two Embarcadero Center, 8th floor, San Francisco, CA 98411 (US).			

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: MULTIVALENT HUMAN-BOVINE ROTAVIRUS VACCINE

(57) Abstract

The present invention provides vaccine compositions for protection against human rotaviral disease without significant reactogenicity. Human x bovine reassortant rotavirus comprising each of the four clinically most important VP7 serotypes of human rotavirus are combined in a multivalent formulation which provides a high degree of infectivity and immunogenicity without producing a transient febrile condition. Methods for producing an immunogenic response without producing a transient febrile condition are also provided.